Lexaria Announces Results From Animal Study GLP-1-A26-1

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC – October 15, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the “ Study ”) that evaluated a number of formulation enhancements using both DehydraTECH-CBD (“ DHT-CBD ”) compositions and DehydraTECH-semaglutide (“ DHT-SEMA ”) glucagon-like peptide-1 (“ GLP-1 ”) compositions to explore the potential for additional improved performance, as well as stake new intellectual property (“ IP ”) claims. Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this new IP. As these patent applications are not yet published, we will not be providing full details of all the specific formulations or outcomes at this time. “We are delighted that certain new formulations in this Study achieved our highest-ever DehydraTECH pharmaceutical-grade relative absorption performance,” said Rich Christopher, CEO of Lexaria Bioscience Corp. “These new formulation enhancements should enable Lexaria t

Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes